← Back to Search

Serotonin Receptor Agonist

Breast Cancer Pts with hyposexual desire disorder/HSDD for Breast Cancer

N/A
Waitlist Available
Led By Shari Goldfarb, MD
Research Sponsored by Memorial Sloan Kettering Cancer Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 1 year
Awards & highlights

Summary

The purpose of this study is to determine if it is feasible for women to take both Flibanserin and tamoxifen for the duration of the study. This study is also trying to find out if Flibanserin improves or has any effect on hyposexual desire disorder/HSDD in women who are taking tamoxifen for breast cancer.

Eligible Conditions
  • Breast Cancer
  • Low Libido

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~1 year
This trial's timeline: 3 weeks for screening, Varies for treatment, and 1 year for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Discontinuation rate of flibanserin in women with breast cancer on Tamoxifen with disease or medical induced hypoactive sexual desire disorder
Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability] of flibanserin

Trial Design

1Treatment groups
Experimental Treatment
Group I: Breast Cancer Pts with hyposexual desire disorder/HSDDExperimental Treatment1 Intervention

Find a Location

Who is running the clinical trial?

Memorial Sloan Kettering Cancer CenterLead Sponsor
1,956 Previous Clinical Trials
595,513 Total Patients Enrolled
205 Trials studying Breast Cancer
83,331 Patients Enrolled for Breast Cancer
Shari Goldfarb, MDPrincipal InvestigatorMemorial Sloan Kettering Cancer Center
8 Previous Clinical Trials
1,363 Total Patients Enrolled
7 Trials studying Breast Cancer
1,313 Patients Enrolled for Breast Cancer
~6 spots leftby Sep 2025